Patents by Inventor Donald Pivonka

Donald Pivonka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy
    Patent number: 9580429
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: February 28, 2017
    Assignee: AstraZeneca AB
    Inventors: Anders Bogevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tiden
  • PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY
    Publication number: 20150099769
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Application
    Filed: September 15, 2014
    Publication date: April 9, 2015
    Inventors: Anders BOGEVIG, Yvonne LO-ALFREDSSON, Donald PIVONKA, Anna-Karin TIDEN
  • Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy
    Patent number: 8859568
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: October 14, 2014
    Assignee: Astrazeneca AB
    Inventors: Anders Bögevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tidén
  • NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY
    Publication number: 20110059996
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Application
    Filed: November 3, 2010
    Publication date: March 10, 2011
    Inventors: Anders BÖGEVIG, Yvonne LO-ALFREDSSON, Donald PIVONKA, Anna-Karin TIDÉN
  • Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy
    Patent number: 7829707
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Grant
    Filed: December 5, 2005
    Date of Patent: November 9, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Bogevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tiden
  • Thioxanthine Derivatives and Their Use as Inhibitors of MPO
    Publication number: 20090286813
    Abstract: There are disclosed novel compounds of Formula (I) wherein R1, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardio- and cerebrovascular atherosclerotic disorders and peripheral artery disease and respiratory disorders.
    Type: Application
    Filed: April 12, 2007
    Publication date: November 19, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Donald Pivonka, Anna-Karin Tiden, Jenny Viklund
  • Novel Pyrrolo [3,2-D]Pyrimidin-4-One Derivatives And Their Use In Therapy
    Publication number: 20080221136
    Abstract: There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the enzyme MPO and are thereby particularly useful in the treatment or prophylaxis of neuroinflammatory disorders, cardiovascular disorders and respiratory disorders.
    Type: Application
    Filed: December 5, 2005
    Publication date: September 11, 2008
    Applicant: AstraZeneca AB
    Inventors: Anders Bogevig, Yvonne Lo-Alfredsson, Donald Pivonka, Anna-Karin Tiden